Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 8/20 | 0.52 |
| ▸ | KDM1B | Q8NB78 | 5/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL249597 | 0.90 | CYP3A4 (0.48) | KDM1AKDM1BCYP3A4TSHRMAPK1 | |
| SCHEMBL832549 | 0.83 | KDM1A (0.41) | KDM1AKDM1BCYP3A4TSHRMAPK1 | |
| SCHEMBL966908 | 0.81 | CYP3A4 (0.55) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL30711810 | 0.81 | KDM1A (0.52) | KDM1AKDM1BCYP3A4TSHRMAPK1 | |
| SCHEMBL29902922 | 0.81 | ALDH1A1 (0.42) | KDM1AKDM1BKCNH2ALDH1A1MEN1 | |
| SCHEMBL29502024 | 0.81 | CYP3A4 (0.55) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL833057 | 0.81 | KDM1A (0.52) | KDM1AKDM1BCYP3A4TSHRMAPK1 | |
| SCHEMBL241198 | 0.81 | ALDH1A1 (0.42) | KDM1AKDM1BKCNH2ALDH1A1MEN1 | |
| SCHEMBL23885388 | 0.79 | ALDH1A1 (0.40) | KDM1AKDM1BKCNH2ALDH1A1MEN1 | |
| SCHEMBL832391 | 0.79 | CYP3A4 (0.60) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282746-A1 | HALOGEN-SUBSTITUTED ISOINDOLINE COMPOUND AND USE THEREOF | Chengdu Fendi Pharmaceutical Co., Ltd. (CN) | 2025-09-11 | — | — | US | disclosed |
| US-20250263753-A1 | BRIDGED CYCLE-BASED INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND APPLICATION IN GENE EDITING | JUNO THERAPEUTICS INC (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250241912-A1 | USE OF BRIDGED CYCLE-BASED INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE IN COMBINATION OF DNA POLYMERASE THETA INHIBITOR AND COMPOSITIONS AND APPLICATION IN GENE EDITING | JUNO THERAPEUTICS INC (US) | 2025-07-31 | — | — | US | disclosed |
| CN-119638639-A | Biaryl compound with anti-cell necrotic apoptosis activity, derivative and application thereof | 中国药科大学 | 2025-03-18 | — | — | CN | disclosed |
| WO-2025049253-A1 | BRIDGED CYCLE‑BASED INHIBITORS OF DNA‑DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND APPLICATION IN GENE EDITING | JUNO THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| EP-4516785-A1 | HALOGEN-SUBSTITUTED ISOINDOLINE COMPOUND AND USE THEREOF | Chengdu Fendi Pharmaceutical Co., Ltd. (CN) | 2025-03-05 | — | — | EP | disclosed |
| CN-118994109-A | Preparation method of lysine-specific demethylase 1 inhibitor | 成都苑东生物制药股份有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| CN-116199667-B | Halogen substituted isoindoline compound and application thereof | 成都分迪药业有限公司 | 2024-05-03 | — | — | CN | disclosed |
| EP-4327877-A2 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| WO-2008144275-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2008-11-27 | — | — | WO | disclosed |
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-20050208582-A1 | Pyrazole compounds and pharmaceutical compositions comprising the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| CN-1655778-A | Methods of treating hepatitis C virus infection using pyranoindole derivatives | WYETH CORP (US) | 2005-08-17 | — | — | CN | disclosed |
| CN-1653069-A | R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease | WYETH CORP (US) | 2005-08-10 | — | — | CN | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-0224001-B1 | ANTHRANILONITRILE DERIVATIVES AND RELATED COMPOUNDS AS USEFUL AGENTS FOR PROMOTING GROWTH, IMPROVING FEED EFFICIENCY, AND FOR INCREASING THE LEAN MEAT TO FAT RATIO OF WARM-BLOODED ANIMALS | AMERICAN CYANAMID COMPANY (US) | 1991-03-20 | — | — | EP | disclosed |
| US-4863959-A | Anthranilonitrile derivatives as useful agents for promoting growth, improving feed efficiency, and for increasing the lean meat to fat ratio of warm-blooded animals | AMERICAN CYANAMID COMPANY (US) | 1989-09-05 | — | — | US | disclosed |
| EP-0224001-A1 | Anthranilonitrile derivatives and related compounds as useful agents for promoting growth, improving feed efficiency, and for increasing the lean meat to fat ratio of warm-blooded animals | AMERICAN CYANAMID COMPANY (US) | 1987-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282746-A1 | HALOGEN-SUBSTITUTED ISOINDOLINE COMPOUND AND USE THEREOF | FLI1, CYP3A7, GTF2I | KDM1A 3884/4885KDM1B 3651/4885CYP3A4 8/4885 |
| US-20250263753-A1 | BRIDGED CYCLE-BASED INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND APPLICATION IN GENE EDITING | DTYMK, DCK, PHKG1 | KDM1A 907/4885KDM1B 883/4885CYP3A4 2002/4885 |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | KDM1A 1556/4885KDM1B 1182/4885CYP3A4 1005/4885 |
| US-20250241912-A1 | USE OF BRIDGED CYCLE-BASED INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE IN COMBINATION OF DNA POLYMERASE THETA INHIBITOR AND COMPOSITIONS AND APPLICATION IN GENE EDITING | POLQ, POLK, POLG | KDM1A 1351/4885KDM1B 1038/4885CYP3A4 1675/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | KDM1A 2941/4885KDM1B 3138/4885CYP3A4 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.